WO2018048046A3 - mTOR 저해제를 함유하는 황반변성 치료용 의약조성물 - Google Patents
mTOR 저해제를 함유하는 황반변성 치료용 의약조성물 Download PDFInfo
- Publication number
- WO2018048046A3 WO2018048046A3 PCT/KR2017/002943 KR2017002943W WO2018048046A3 WO 2018048046 A3 WO2018048046 A3 WO 2018048046A3 KR 2017002943 W KR2017002943 W KR 2017002943W WO 2018048046 A3 WO2018048046 A3 WO 2018048046A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- macular degeneration
- pharmaceutical composition
- composition containing
- treating macular
- mtor inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 황반변성 치료용 의약조성물에 관한 것으로, 더욱 자세하게는 mTOR 유전자의 발현을 저해하는 저해제를 함유하는 황반변성 치료용 의약조성물에 관한 것이다. 성인 실명의 원인이 되는 대표적인 망막질환인 나이관련 황반변성을 효과적으로 치료할 수 있다.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17848931.6A EP3517133B1 (en) | 2016-09-09 | 2017-03-17 | Pharmaceutical composition containing mtor inhibitor for treating macular degeneration |
| CN201780062349.XA CN109937053B (zh) | 2016-09-09 | 2017-03-17 | 用于治疗黄斑变性的含有mTOR抑制剂的药物组合物 |
| CA3035675A CA3035675C (en) | 2016-09-09 | 2017-03-17 | Pharmaceutical composition containing mtor inhibitor for treating macular degeneration |
| AU2017323898A AU2017323898B2 (en) | 2016-09-09 | 2017-03-17 | Pharmaceutical composition containing mTOR inhibitor for treating macular degeneration |
| JP2019514034A JP6931046B2 (ja) | 2016-09-09 | 2017-03-17 | ｍＴＯＲ阻害剤を含有する黄斑変性治療用薬学組成物 |
| US16/327,850 US10583150B2 (en) | 2016-09-09 | 2017-03-17 | Pharmaceutical composition containing mTOR inhibitor for treating macular degeneration |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0116310 | 2016-09-09 | ||
| KR20160116310 | 2016-09-09 | ||
| KR1020170033986A KR101951787B1 (ko) | 2016-09-09 | 2017-03-17 | mTOR 저해제를 함유하는 황반변성 치료용 의약조성물 |
| KR10-2017-0033986 | 2017-03-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2018048046A2 WO2018048046A2 (ko) | 2018-03-15 |
| WO2018048046A3 true WO2018048046A3 (ko) | 2018-09-07 |
Family
ID=61562756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2017/002943 WO2018048046A2 (ko) | 2016-09-09 | 2017-03-17 | mTOR 저해제를 함유하는 황반변성 치료용 의약조성물 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018048046A2 (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024521770A (ja) * | 2021-05-26 | 2024-06-04 | ユニティ バイオテクノロジー インコーポレイテッド | 網膜血管症を治療する方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009143371A2 (en) * | 2008-05-21 | 2009-11-26 | Intradigm Corporation | COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF |
| WO2010064851A2 (ko) * | 2008-12-02 | 2010-06-10 | 울산대학교 산학협력단 | 종간 교차활성을 지닌 ｍＴＯＲ을 표적으로 하는 ｓｉＲＮＡ, 이를 포함하는 재조합벡터 및 이를 함유하는 약학조성물 |
| US20120114637A1 (en) * | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
| WO2013056105A2 (en) * | 2011-10-13 | 2013-04-18 | The Johns Hopkins University | INHIBITION OF SPINAL MAMMALIAN TARGET OF RAPAMYCIN (mTOR) REDUCES CANCER PAIN, OPIOID TOLERANCE, AND HYPERALGESIA |
-
2017
- 2017-03-17 WO PCT/KR2017/002943 patent/WO2018048046A2/ko unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009143371A2 (en) * | 2008-05-21 | 2009-11-26 | Intradigm Corporation | COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF |
| WO2010064851A2 (ko) * | 2008-12-02 | 2010-06-10 | 울산대학교 산학협력단 | 종간 교차활성을 지닌 ｍＴＯＲ을 표적으로 하는 ｓｉＲＮＡ, 이를 포함하는 재조합벡터 및 이를 함유하는 약학조성물 |
| US20120114637A1 (en) * | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
| WO2013056105A2 (en) * | 2011-10-13 | 2013-04-18 | The Johns Hopkins University | INHIBITION OF SPINAL MAMMALIAN TARGET OF RAPAMYCIN (mTOR) REDUCES CANCER PAIN, OPIOID TOLERANCE, AND HYPERALGESIA |
Non-Patent Citations (2)
| Title |
|---|
| JOHNSON, S. C. ET AL.: "mTOR Is a Key Modulator of Ageing and Age-related Diseas e", NATURE, vol. 493, 2013, pages 338 - 345, XP055489566 * |
| See also references of EP3517133A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018048046A2 (ko) | 2018-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500828A1 (en) | Jak kinase inhibitor compounds for treatment of respiratory disease | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| EP3968996A4 (en) | TRIARYL COMPOUNDS FOR THE TREATMENT OF PD-L1 DISEASES | |
| BR112017017078A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença. | |
| MA40240B1 (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
| EP3986392A4 (en) | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | |
| SG10201811175WA (en) | Method for treating cancer using a combination of chk1 and atr inhibitors | |
| TN2017000134A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| EA201790889A1 (ru) | Офтальмологический раствор | |
| WO2020021477A3 (en) | Compositions and methods for treating the eye | |
| EP3377630A4 (en) | TREATMENT OF AGE-RELATED MACULAR DEGENERATION USING RNA COMPLEXES THAT TARGET MYD88 OR TLR3 | |
| MX2017011277A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| AU2017248276A1 (en) | Methods of treating ocular conditions | |
| EP3176163A4 (en) | Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient | |
| WO2018125800A3 (en) | Metalloenzyme inhibitor compounds | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| EP3886852A4 (en) | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | |
| BR112016016901A2 (pt) | agentes para o uso no tratamento de inflamação retinal | |
| EP3709982A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS AND SKIN DISEASES | |
| MX2018015548A (es) | Inhibidores mitocondriales para el tratamiento de trastornos de proliferacion. | |
| WO2018048046A3 (ko) | mTOR 저해제를 함유하는 황반변성 치료용 의약조성물 | |
| WO2018125799A3 (en) | Metalloenzyme inhibitor compounds | |
| MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17848931 Country of ref document: EP Kind code of ref document: A2 |
|
| ENP | Entry into the national phase |
Ref document number: 3035675 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2019514034 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2017323898 Country of ref document: AU Date of ref document: 20170317 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2017848931 Country of ref document: EP Effective date: 20190409 |